United Kingdom · Question · Written question
UIN 12336
Aducanumab
Introduced
8 June 2021
Last action
2 July 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
2 July 2021
Summary
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential merits of the Alzheimer’s drug Aduhelm.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
8 June 2021
Written question
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential merits of the Alzheimer’s drug Aduhelm.
Source: Commons
2 July 2021
Answer
The Medicines and Healthcare products Regulatory Agency (MHRA) is monitoring regulatory developments regarding Aducanumab (Aduhelm). We are unable to formally comment on any product that is not approved for use in the United Kingdom due to commercial and ...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-06-08/12336
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1330641
- uk · wq-1330641 · source updated 2 July 2021